Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9287299 | 0.85 | KDM4E (0.34) | KDM4EALDH1A1LMNA | |
| SCHEMBL15434679 | 0.82 | HEXA (0.37) | KDM4EALDH1A1LMNACYP1A2NUDT1 | |
| SCHEMBL15429583 | 0.82 | ALDH1A1 (0.31) | KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL9286483 | 0.79 | KDM4E (0.42) | KDM4EALDH1A1LMNACYP1A2HPGD | |
| SCHEMBL8637167 | 0.75 | KDM4E (0.34) | KDM4EALDH1A1LMNACYP1A2HPGD | |
| SCHEMBL3393860 | 0.73 | ADORA2A (0.38) | LMNA | |
| Isopropyl Alcohol SCHEMBL9446136 | 0.72 | LMNA (0.46) | KDM4EALDH1A1LMNACYP1A2NOS2 | |
| Isopropyl Alcohol SCHEMBL9562856 | 0.72 | LMNA (0.46) | KDM4EALDH1A1LMNACYP1A2NOS2 | |
| Isopropyl Alcohol SCHEMBL9446138 | 0.72 | LMNA (0.46) | KDM4EALDH1A1LMNACYP1A2NOS2 | |
| SCHEMBL15429599 | 0.71 | KDM4E (0.36) | KDM4EALDH1A1LMNACYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073628-A1 | BENZOXAZEPINES ASN INHIBITORS OF P13K/M TOR AND METHODS OF THEIR USE AND MANUFACTURE | RICE KENNETH D (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140018347-A1 | BENZOXAZEPINES AS INHIBITORS OF mTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018347-A1 | BENZOXAZEPINES AS INHIBITORS OF mTOR AND METHODS OF THEIR USE AND MANUFACTURE | MTOR, RICTOR, RPTOR | KDM4E 223/4885ALDH1A1 3330/4885LMNA 2517/4885 |
| US-20140073628-A1 | BENZOXAZEPINES ASN INHIBITORS OF P13K/M TOR AND METHODS OF THEIR USE AND MANUFACTURE | MTOR, RPTOR, RICTOR | KDM4E 567/4885ALDH1A1 4794/4885LMNA 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.